Experimental RNA Therapy Reduces Muscle Loss in GLP-1 Treatments

Industry Pulse News Desk · 2026-10-04

Researchers have identified an RNA-based treatment that enhances fat loss while preserving lean muscle mass when paired with semaglutide.

An experimental RNA-based therapy combined with semaglutide may increase fat loss while limiting the reduction of lean muscle mass, according to new study results. The findings address a primary side effect of popular GLP-1 weight-loss medications, which often cause patients to lose muscle tissue alongside fat.

Semaglutide, the active ingredient in widely prescribed diabetes and obesity treatments, works by mimicking hormones that regulate appetite and blood sugar levels. While the medication is highly effective at driving overall weight reduction, clinical data shows that a significant portion of the weight lost can consist of lean muscle mass.

The novel RNA treatment targets specific biological pathways to direct metabolic weight loss toward adipose tissue. In preliminary research, combining the experimental therapy with standard semaglutide dosing helped subjects burn a higher proportion of body fat while preserving existing muscle structure.

Preserving muscle mass is critical for maintaining metabolic rate, physical function, and long-term health outcomes in patients undergoing medical weight management. Researchers noted that mitigating muscle loss could also lower the risk of weight regain following the cessation of GLP-1 treatments.

The combination approach represents a broader push within the pharmaceutical industry to refine obesity care. Drug developers are actively seeking companion therapies to enhance the quality of weight loss as global demand for prescription anti-obesity medications continues to grow.